Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence - 2Remote Work Survival manual: Helping Efficiency at Home
- 3Find Your Internal Culinary expert: Cooking Strategies and Recipes
- 4Select Your Go-To Bluetooth Earphones
- 5Underestimated Metropolitan Experience Urban communities On the planet
- 6 Financial plan 3D Printers with the Best Worth
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- 6 Web-based Staple Help You Can Trust
- Japanese H3 rocket fails during launch of navigation satellite (video)
- Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
- 2 new malaria treatments announced as drug resistance grows
- Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
